 Charles Daley
Concepts (441)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 80 | 2023 | 334 | 14.880 |
Why?
| | Mycobacterium avium-intracellulare Infection | 26 | 2023 | 62 | 8.210 |
Why?
| | Mycobacterium avium Complex | 41 | 2023 | 93 | 7.790 |
Why?
| | Mycobacterium abscessus | 29 | 2023 | 97 | 6.600 |
Why?
| | Lung Diseases | 39 | 2023 | 718 | 6.300 |
Why?
| | Antitubercular Agents | 36 | 2021 | 163 | 5.990 |
Why?
| | Tuberculosis | 31 | 2021 | 240 | 5.530 |
Why?
| | Nontuberculous Mycobacteria | 46 | 2023 | 206 | 5.500 |
Why?
| | Anti-Bacterial Agents | 53 | 2023 | 1510 | 4.720 |
Why?
| | Tuberculosis, Pulmonary | 23 | 2021 | 112 | 4.480 |
Why?
| | Tuberculosis, Multidrug-Resistant | 12 | 2019 | 45 | 3.780 |
Why?
| | Mycobacterium Infections | 12 | 2019 | 61 | 3.670 |
Why?
| | Mycobacterium kansasii | 10 | 2020 | 14 | 3.360 |
Why?
| | Mycobacterium | 15 | 2023 | 103 | 3.100 |
Why?
| | Mycobacterium tuberculosis | 26 | 2019 | 266 | 3.070 |
Why?
| | Cystic Fibrosis | 20 | 2023 | 964 | 2.970 |
Why?
| | Bronchiectasis | 17 | 2023 | 105 | 2.800 |
Why?
| | Amikacin | 15 | 2023 | 21 | 2.740 |
Why?
| | Macrolides | 15 | 2023 | 57 | 2.660 |
Why?
| | Drug Resistance, Bacterial | 21 | 2023 | 155 | 2.260 |
Why?
| | Interferon-gamma Release Tests | 6 | 2016 | 30 | 2.070 |
Why?
| | Sputum | 25 | 2020 | 290 | 1.790 |
Why?
| | Latent Tuberculosis | 8 | 2017 | 69 | 1.400 |
Why?
| | Pneumonia, Bacterial | 6 | 2017 | 110 | 1.370 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2016 | 113 | 1.310 |
Why?
| | Humans | 177 | 2023 | 118972 | 1.300 |
Why?
| | Clofazimine | 4 | 2021 | 14 | 1.250 |
Why?
| | Pneumonia | 5 | 2023 | 592 | 1.150 |
Why?
| | Antibiotics, Antitubercular | 7 | 2021 | 35 | 1.130 |
Why?
| | Rifampin | 12 | 2021 | 69 | 1.120 |
Why?
| | Clarithromycin | 13 | 2023 | 28 | 1.060 |
Why?
| | HIV Infections | 15 | 2022 | 2459 | 0.990 |
Why?
| | Drug Therapy, Combination | 18 | 2022 | 965 | 0.990 |
Why?
| | Microbial Sensitivity Tests | 20 | 2023 | 302 | 0.980 |
Why?
| | Oxazolidinones | 3 | 2013 | 14 | 0.970 |
Why?
| | Acetamides | 3 | 2013 | 26 | 0.970 |
Why?
| | Ethambutol | 10 | 2021 | 20 | 0.920 |
Why?
| | Global Health | 7 | 2018 | 310 | 0.920 |
Why?
| | Disease Outbreaks | 5 | 2019 | 322 | 0.860 |
Why?
| | Tuberculin Test | 6 | 2016 | 36 | 0.850 |
Why?
| | Equipment Contamination | 2 | 2019 | 55 | 0.820 |
Why?
| | Aged | 52 | 2021 | 19657 | 0.810 |
Why?
| | Professional Practice Gaps | 1 | 2020 | 10 | 0.760 |
Why?
| | Treatment Outcome | 29 | 2023 | 9342 | 0.760 |
Why?
| | Middle Aged | 59 | 2021 | 27617 | 0.730 |
Why?
| | Disease Management | 4 | 2021 | 571 | 0.710 |
Why?
| | San Francisco | 10 | 2014 | 57 | 0.660 |
Why?
| | Molecular Epidemiology | 4 | 2006 | 69 | 0.650 |
Why?
| | Male | 74 | 2023 | 57801 | 0.630 |
Why?
| | Female | 73 | 2023 | 61564 | 0.610 |
Why?
| | Adult | 48 | 2023 | 31512 | 0.610 |
Why?
| | Health Care Sector | 2 | 2013 | 26 | 0.570 |
Why?
| | Extensively Drug-Resistant Tuberculosis | 2 | 2013 | 6 | 0.560 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2019 | 63 | 0.560 |
Why?
| | Azithromycin | 6 | 2021 | 81 | 0.550 |
Why?
| | Phylogeny | 5 | 2021 | 816 | 0.550 |
Why?
| | Genome, Bacterial | 5 | 2021 | 109 | 0.530 |
Why?
| | Lung | 15 | 2023 | 3664 | 0.530 |
Why?
| | Retrospective Studies | 28 | 2022 | 12978 | 0.530 |
Why?
| | Linezolid | 4 | 2018 | 16 | 0.500 |
Why?
| | United States | 30 | 2022 | 12555 | 0.490 |
Why?
| | Sex Factors | 1 | 2019 | 1781 | 0.470 |
Why?
| | Communicable Disease Control | 1 | 2014 | 72 | 0.460 |
Why?
| | Serologic Tests | 1 | 2012 | 52 | 0.440 |
Why?
| | Practice Guidelines as Topic | 6 | 2015 | 1440 | 0.430 |
Why?
| | Professional Practice | 1 | 2012 | 62 | 0.430 |
Why?
| | Rifabutin | 2 | 2012 | 5 | 0.410 |
Why?
| | Opportunistic Infections | 1 | 2011 | 42 | 0.410 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 100 | 0.410 |
Why?
| | Occupational Health | 1 | 2013 | 172 | 0.380 |
Why?
| | Mass Screening | 3 | 2016 | 1052 | 0.370 |
Why?
| | Recurrence | 10 | 2019 | 975 | 0.370 |
Why?
| | Occupational Exposure | 1 | 2013 | 277 | 0.370 |
Why?
| | Cardiac Surgical Procedures | 3 | 2019 | 461 | 0.350 |
Why?
| | Aged, 80 and over | 14 | 2021 | 6561 | 0.350 |
Why?
| | Administration, Inhalation | 6 | 2021 | 656 | 0.350 |
Why?
| | Pyrazinamide | 3 | 2021 | 6 | 0.340 |
Why?
| | Incidence | 10 | 2019 | 2424 | 0.340 |
Why?
| | Antigens, Bacterial | 5 | 2012 | 116 | 0.320 |
Why?
| | Directly Observed Therapy | 2 | 2005 | 14 | 0.310 |
Why?
| | Health Personnel | 3 | 2014 | 588 | 0.310 |
Why?
| | Drug Administration Schedule | 6 | 2020 | 736 | 0.300 |
Why?
| | Tuberculosis, Pleural | 2 | 2003 | 6 | 0.300 |
Why?
| | Organ Transplantation | 1 | 2009 | 165 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 610 | 0.290 |
Why?
| | Quality of Life | 5 | 2023 | 2366 | 0.290 |
Why?
| | Morbidity | 2 | 2019 | 296 | 0.280 |
Why?
| | Genomics | 4 | 2021 | 706 | 0.270 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1284 | 0.270 |
Why?
| | Diarylquinolines | 2 | 2019 | 5 | 0.270 |
Why?
| | Disease Progression | 6 | 2020 | 2490 | 0.270 |
Why?
| | ROC Curve | 4 | 2020 | 473 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 8 | 2020 | 2436 | 0.270 |
Why?
| | World Health Organization | 2 | 2018 | 107 | 0.270 |
Why?
| | Mutation | 5 | 2019 | 3457 | 0.260 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 88 | 0.260 |
Why?
| | Prospective Studies | 13 | 2023 | 6471 | 0.260 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 56 | 0.260 |
Why?
| | Drug Synergism | 3 | 2021 | 339 | 0.250 |
Why?
| | Water Microbiology | 1 | 2005 | 78 | 0.250 |
Why?
| | Contact Tracing | 1 | 2004 | 16 | 0.250 |
Why?
| | DNA Fingerprinting | 1 | 2004 | 26 | 0.250 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2005 | 83 | 0.240 |
Why?
| | Biomarkers | 3 | 2020 | 3588 | 0.240 |
Why?
| | DNA, Bacterial | 3 | 2021 | 314 | 0.240 |
Why?
| | Research | 2 | 2018 | 411 | 0.240 |
Why?
| | Self Administration | 1 | 2004 | 125 | 0.240 |
Why?
| | Biomedical Research | 5 | 2020 | 612 | 0.240 |
Why?
| | Medical Tourism | 1 | 2023 | 10 | 0.230 |
Why?
| | Imipenem | 5 | 2022 | 17 | 0.230 |
Why?
| | Registries | 5 | 2020 | 1810 | 0.230 |
Why?
| | Risk Factors | 8 | 2019 | 9000 | 0.230 |
Why?
| | London | 1 | 2023 | 42 | 0.230 |
Why?
| | Leprostatic Agents | 1 | 2022 | 3 | 0.230 |
Why?
| | Pneumonectomy | 2 | 2016 | 115 | 0.220 |
Why?
| | Adolescent | 17 | 2021 | 18480 | 0.220 |
Why?
| | Republic of Korea | 6 | 2019 | 26 | 0.220 |
Why?
| | Administration, Oral | 3 | 2020 | 756 | 0.220 |
Why?
| | Meningitis | 1 | 2023 | 74 | 0.210 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2220 | 0.210 |
Why?
| | Spectinomycin | 1 | 2021 | 2 | 0.210 |
Why?
| | Thorax | 1 | 2022 | 45 | 0.210 |
Why?
| | beta-Lactams | 1 | 2022 | 28 | 0.210 |
Why?
| | Time Factors | 7 | 2020 | 6412 | 0.200 |
Why?
| | Comorbidity | 4 | 2019 | 1527 | 0.200 |
Why?
| | Cohort Studies | 8 | 2020 | 5116 | 0.200 |
Why?
| | Safety | 1 | 2003 | 304 | 0.200 |
Why?
| | Young Adult | 10 | 2019 | 10793 | 0.200 |
Why?
| | Bacteriophages | 1 | 2022 | 76 | 0.190 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 5 | 0.190 |
Why?
| | Oxazepines | 1 | 2020 | 4 | 0.190 |
Why?
| | Prevalence | 4 | 2019 | 2326 | 0.190 |
Why?
| | Serine Proteases | 1 | 2020 | 15 | 0.190 |
Why?
| | Benzoxazoles | 1 | 2020 | 16 | 0.190 |
Why?
| | Peptidyl Transferases | 1 | 2020 | 7 | 0.190 |
Why?
| | Cluster Analysis | 4 | 2020 | 481 | 0.190 |
Why?
| | Respiratory Therapy | 1 | 2020 | 19 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4596 | 0.180 |
Why?
| | Area Under Curve | 3 | 2020 | 296 | 0.180 |
Why?
| | Nitroimidazoles | 1 | 2019 | 6 | 0.180 |
Why?
| | Mycobacterium fortuitum | 1 | 2019 | 2 | 0.180 |
Why?
| | Oxazoles | 1 | 2019 | 31 | 0.180 |
Why?
| | Cost of Illness | 1 | 2021 | 258 | 0.180 |
Why?
| | Durable Medical Equipment | 1 | 2019 | 4 | 0.170 |
Why?
| | Genotyping Techniques | 1 | 2019 | 75 | 0.170 |
Why?
| | Anti-HIV Agents | 3 | 2016 | 664 | 0.170 |
Why?
| | Patient Selection | 1 | 2003 | 676 | 0.170 |
Why?
| | DNA Gyrase | 1 | 2018 | 12 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 1945 | 0.170 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 119 | 0.170 |
Why?
| | Bronchoscopy | 1 | 2020 | 247 | 0.160 |
Why?
| | Genotype | 6 | 2019 | 1882 | 0.160 |
Why?
| | Aza Compounds | 2 | 2010 | 12 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 245 | 0.160 |
Why?
| | Hospitals | 1 | 2023 | 598 | 0.160 |
Why?
| | Patient Compliance | 3 | 2011 | 537 | 0.160 |
Why?
| | Respiratory System Agents | 1 | 2018 | 22 | 0.160 |
Why?
| | Musculoskeletal Diseases | 1 | 2019 | 68 | 0.160 |
Why?
| | Internationality | 1 | 2019 | 152 | 0.160 |
Why?
| | Treatment Failure | 3 | 2019 | 341 | 0.160 |
Why?
| | Tuberculosis Vaccines | 2 | 2010 | 3 | 0.160 |
Why?
| | Isoniazid | 3 | 2019 | 53 | 0.160 |
Why?
| | Liposomes | 1 | 2018 | 151 | 0.150 |
Why?
| | Radiography, Thoracic | 2 | 2017 | 164 | 0.150 |
Why?
| | Forced Expiratory Volume | 5 | 2020 | 520 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2018 | 130 | 0.150 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 104 | 0.150 |
Why?
| | Elephants | 1 | 2017 | 4 | 0.150 |
Why?
| | Quinolines | 2 | 2010 | 128 | 0.150 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2018 | 79 | 0.150 |
Why?
| | Fluoroquinolones | 3 | 2018 | 42 | 0.150 |
Why?
| | Prognosis | 5 | 2020 | 3443 | 0.150 |
Why?
| | Agammaglobulinemia | 1 | 2017 | 32 | 0.150 |
Why?
| | Pulmonary Medicine | 1 | 2018 | 85 | 0.150 |
Why?
| | Interferon-gamma | 4 | 2007 | 736 | 0.150 |
Why?
| | Kartagener Syndrome | 1 | 2016 | 25 | 0.150 |
Why?
| | Surgical Equipment | 1 | 2016 | 13 | 0.150 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1795 | 0.150 |
Why?
| | Databases, Genetic | 1 | 2018 | 253 | 0.140 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 346 | 0.140 |
Why?
| | Child | 10 | 2021 | 19129 | 0.140 |
Why?
| | Levofloxacin | 1 | 2016 | 22 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 251 | 0.140 |
Why?
| | Genes, Bacterial | 1 | 2016 | 162 | 0.140 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 75 | 0.140 |
Why?
| | Public Health | 4 | 2016 | 450 | 0.140 |
Why?
| | Cough | 3 | 2023 | 102 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 521 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1597 | 0.130 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 122 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2445 | 0.130 |
Why?
| | Chronic Disease | 3 | 2023 | 1636 | 0.130 |
Why?
| | Drug Tolerance | 1 | 2015 | 78 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2016 | 262 | 0.120 |
Why?
| | DNA Transposable Elements | 2 | 2006 | 102 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 687 | 0.120 |
Why?
| | Cross Infection | 1 | 2016 | 205 | 0.120 |
Why?
| | Sequence Analysis, DNA | 2 | 2014 | 755 | 0.120 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2007 | 260 | 0.120 |
Why?
| | Computational Biology | 1 | 2018 | 588 | 0.120 |
Why?
| | Genetic Variation | 2 | 2021 | 926 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 2 | 2004 | 267 | 0.120 |
Why?
| | Societies, Medical | 4 | 2020 | 703 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 465 | 0.120 |
Why?
| | MicroRNAs | 1 | 2020 | 637 | 0.110 |
Why?
| | Colorado | 4 | 2022 | 4196 | 0.110 |
Why?
| | Transcriptome | 2 | 2015 | 756 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2018 | 497 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1244 | 0.110 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2015 | 279 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2017 | 545 | 0.110 |
Why?
| | Contraindications | 1 | 2012 | 86 | 0.110 |
Why?
| | Glycolipids | 1 | 2012 | 37 | 0.110 |
Why?
| | Models, Statistical | 1 | 2016 | 636 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 195 | 0.110 |
Why?
| | Consensus | 3 | 2022 | 534 | 0.110 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 126 | 0.100 |
Why?
| | Cytokines | 2 | 2011 | 1900 | 0.100 |
Why?
| | Drug Resistance, Multiple | 1 | 2011 | 19 | 0.100 |
Why?
| | beta-Lactamase Inhibitors | 2 | 2022 | 3 | 0.100 |
Why?
| | Immunoglobulin A | 1 | 2012 | 174 | 0.100 |
Why?
| | Drug Interactions | 1 | 2012 | 352 | 0.100 |
Why?
| | Debridement | 1 | 2011 | 79 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 842 | 0.100 |
Why?
| | Virulence | 1 | 2011 | 240 | 0.100 |
Why?
| | Metagenomics | 2 | 2021 | 134 | 0.100 |
Why?
| | Hospitals, General | 2 | 2014 | 19 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 331 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 969 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2020 | 3171 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2012 | 263 | 0.090 |
Why?
| | Hepatitis, Viral, Human | 1 | 2009 | 26 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 1137 | 0.090 |
Why?
| | Netherlands | 2 | 2012 | 62 | 0.090 |
Why?
| | Bacteriological Techniques | 1 | 2009 | 66 | 0.090 |
Why?
| | Forkhead Transcription Factors | 2 | 2007 | 182 | 0.090 |
Why?
| | Hospitalization | 1 | 2018 | 1785 | 0.090 |
Why?
| | Confidence Intervals | 2 | 2015 | 324 | 0.090 |
Why?
| | Child, Preschool | 4 | 2016 | 9491 | 0.090 |
Why?
| | Interleukins | 2 | 2007 | 242 | 0.080 |
Why?
| | Vitamins | 1 | 2010 | 158 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1125 | 0.080 |
Why?
| | Early Diagnosis | 1 | 2009 | 230 | 0.080 |
Why?
| | RNA, Ribosomal, 23S | 2 | 2018 | 12 | 0.080 |
Why?
| | Interleukin-9 | 1 | 2007 | 11 | 0.080 |
Why?
| | Logistic Models | 3 | 2019 | 1901 | 0.080 |
Why?
| | Radiography | 2 | 2008 | 861 | 0.080 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 42 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1267 | 0.080 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2007 | 6 | 0.080 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2007 | 40 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2020 | 1687 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2020 | 204 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 69 | 0.070 |
Why?
| | Th1 Cells | 1 | 2007 | 133 | 0.070 |
Why?
| | Survivors | 1 | 2010 | 418 | 0.070 |
Why?
| | Vitamin D | 1 | 2010 | 354 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2062 | 0.070 |
Why?
| | Interleukin-8 | 1 | 2007 | 249 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 2995 | 0.070 |
Why?
| | Animals | 6 | 2021 | 33381 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 681 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2005 | 8 | 0.070 |
Why?
| | Coinfection | 2 | 2018 | 119 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4708 | 0.070 |
Why?
| | Regression Analysis | 1 | 2008 | 983 | 0.070 |
Why?
| | Antirheumatic Agents | 1 | 2007 | 254 | 0.060 |
Why?
| | Europe | 2 | 2016 | 356 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 208 | 0.060 |
Why?
| | Respiratory Function Tests | 2 | 2016 | 526 | 0.060 |
Why?
| | Mycobacterium xenopi | 2 | 2014 | 4 | 0.060 |
Why?
| | Streptomycin | 1 | 2003 | 14 | 0.060 |
Why?
| | Carrier State | 1 | 2004 | 57 | 0.060 |
Why?
| | Cefoxitin | 2 | 2016 | 9 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1079 | 0.060 |
Why?
| | Medicare | 2 | 2019 | 663 | 0.060 |
Why?
| | Influenza, Human | 1 | 2009 | 554 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 394 | 0.060 |
Why?
| | Pseudomonas Infections | 2 | 2016 | 193 | 0.060 |
Why?
| | Substance Abuse, Intravenous | 1 | 2004 | 80 | 0.060 |
Why?
| | Dust | 1 | 2023 | 88 | 0.060 |
Why?
| | Databases, Factual | 2 | 2019 | 1231 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 1868 | 0.060 |
Why?
| | Homosexuality, Male | 1 | 2004 | 166 | 0.060 |
Why?
| | Liver Function Tests | 1 | 2003 | 107 | 0.060 |
Why?
| | Survival Rate | 1 | 2007 | 1720 | 0.050 |
Why?
| | Cefuroxime | 1 | 2022 | 2 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2007 | 1171 | 0.050 |
Why?
| | Mice | 3 | 2021 | 15520 | 0.050 |
Why?
| | Drug Costs | 1 | 2003 | 94 | 0.050 |
Why?
| | Los Angeles | 1 | 2002 | 60 | 0.050 |
Why?
| | Amoxicillin | 1 | 2022 | 20 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2022 | 26 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2007 | 759 | 0.050 |
Why?
| | Peptidoglycan | 1 | 2021 | 28 | 0.050 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2003 | 136 | 0.050 |
Why?
| | Phenotype | 2 | 2021 | 3003 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2020 | 2874 | 0.050 |
Why?
| | Lactams | 1 | 2021 | 38 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2005 | 482 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 248 | 0.050 |
Why?
| | Carboxypeptidases | 1 | 2020 | 14 | 0.050 |
Why?
| | Azabicyclo Compounds | 1 | 2020 | 5 | 0.050 |
Why?
| | Water | 1 | 2023 | 425 | 0.050 |
Why?
| | Cephalosporins | 1 | 2020 | 27 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 80 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 333 | 0.050 |
Why?
| | Gene Ontology | 1 | 2020 | 55 | 0.050 |
Why?
| | Chimera | 1 | 2019 | 60 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1474 | 0.040 |
Why?
| | Drug Monitoring | 2 | 2016 | 187 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 175 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 456 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 58 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3057 | 0.040 |
Why?
| | Population Surveillance | 1 | 2002 | 413 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 559 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1206 | 0.040 |
Why?
| | Ribosomal Proteins | 1 | 2018 | 68 | 0.040 |
Why?
| | Meat | 1 | 2019 | 89 | 0.040 |
Why?
| | Prosthesis-Related Infections | 1 | 2019 | 73 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 95 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 67 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 239 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 123 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1489 | 0.040 |
Why?
| | Animals, Zoo | 1 | 2017 | 12 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 827 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 177 | 0.040 |
Why?
| | Methyltransferases | 1 | 2017 | 61 | 0.040 |
Why?
| | Otitis | 1 | 2016 | 9 | 0.040 |
Why?
| | Pseudomonas | 1 | 2016 | 27 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2017 | 154 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2016 | 67 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2023 | 867 | 0.040 |
Why?
| | Micronesia | 1 | 2016 | 3 | 0.040 |
Why?
| | Needs Assessment | 1 | 2018 | 327 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 73 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 300 | 0.030 |
Why?
| | Mycobacterium chelonae | 1 | 2016 | 8 | 0.030 |
Why?
| | Spirometry | 1 | 2016 | 263 | 0.030 |
Why?
| | Vital Capacity | 1 | 2016 | 260 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 291 | 0.030 |
Why?
| | Bronchi | 1 | 2017 | 242 | 0.030 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2016 | 26 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 278 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2016 | 210 | 0.030 |
Why?
| | Rhinitis | 1 | 2016 | 129 | 0.030 |
Why?
| | Uganda | 1 | 2015 | 74 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 509 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 483 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 244 | 0.030 |
Why?
| | Sinusitis | 1 | 2016 | 175 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 969 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2015 | 2657 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 248 | 0.030 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 155 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 115 | 0.030 |
Why?
| | Mycobacterium avium | 1 | 2013 | 22 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 699 | 0.030 |
Why?
| | Greece | 1 | 2012 | 8 | 0.030 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2012 | 7 | 0.030 |
Why?
| | Mycolic Acids | 1 | 2012 | 6 | 0.030 |
Why?
| | Iran | 1 | 2012 | 37 | 0.030 |
Why?
| | Sweden | 1 | 2012 | 63 | 0.030 |
Why?
| | Bacterial Typing Techniques | 1 | 2012 | 43 | 0.030 |
Why?
| | Geography | 1 | 2013 | 190 | 0.030 |
Why?
| | Italy | 1 | 2012 | 90 | 0.030 |
Why?
| | Developing Countries | 2 | 2005 | 255 | 0.030 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2012 | 52 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 93 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 129 | 0.030 |
Why?
| | Species Specificity | 1 | 2013 | 565 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2016 | 648 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2011 | 63 | 0.030 |
Why?
| | Microspheres | 1 | 2011 | 130 | 0.030 |
Why?
| | Drug Discovery | 1 | 2012 | 124 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 305 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 273 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2092 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2015 | 502 | 0.020 |
Why?
| | Demography | 1 | 2011 | 274 | 0.020 |
Why?
| | Postoperative Care | 1 | 2012 | 237 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1094 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 454 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 845 | 0.020 |
Why?
| | Hepatitis, Chronic | 1 | 2009 | 5 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 514 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 332 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 4552 | 0.020 |
Why?
| | Fatty Acids | 1 | 2012 | 407 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 362 | 0.020 |
Why?
| | Pleural Diseases | 1 | 2009 | 21 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 351 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1487 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1323 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 467 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2009 | 147 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1132 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 57 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2871 | 0.020 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 464 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 68 | 0.020 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 18 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 265 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 288 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2513 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2006 | 14 | 0.020 |
Why?
| | Bone Diseases | 1 | 2007 | 59 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 89 | 0.020 |
Why?
| | Africa | 1 | 2006 | 100 | 0.020 |
Why?
| | Infection Control | 1 | 2007 | 135 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2007 | 360 | 0.020 |
Why?
| | Skin Diseases | 1 | 2007 | 125 | 0.020 |
Why?
| | India | 1 | 2005 | 141 | 0.020 |
Why?
| | Virus Latency | 1 | 2005 | 84 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2012 | 772 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2007 | 442 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 872 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 227 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2009 | 586 | 0.020 |
Why?
| | Cost Savings | 1 | 2004 | 77 | 0.010 |
Why?
| | Asthma | 1 | 2016 | 2158 | 0.010 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2003 | 5 | 0.010 |
Why?
| | Pleura | 1 | 2003 | 18 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 2003 | 24 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 202 | 0.010 |
Why?
| | Pleural Effusion | 1 | 2003 | 47 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 4908 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3730 | 0.010 |
Why?
| | Infant | 1 | 2016 | 8293 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 111 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2674 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 525 | 0.010 |
Why?
| | Rural Population | 1 | 2005 | 452 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2003 | 238 | 0.010 |
Why?
| | Health Policy | 1 | 2004 | 333 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1794 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 336 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2004 | 554 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2004 | 556 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|